ABSCINT is a Belgium-based biotechnology company, specialising in advanced molecular imaging diagnostics. It focuses on utilising single-domain antibodies (sdAbs) to develop innovative positron emission tomography (PET) tracers, enabling in vivo imaging of specific targets. ABSCINT aims to revolutionise cancer diagnostics by equipping clinicians with tools that enhance disease detection, characterisation, and personalised treatment planning.The cornerstone of ABSCINT’s technology is its proprietary single-domain antibody platform, offering unmatched specificity and binding affinity for targets like HER2. These sdAbs are compact, highly stable, and uniquely suited for fast, accurate imaging.
ABSCINT’s flagship product, an anti-HER2 PET tracer, enables whole-body imaging to identify HER2 expression heterogeneity, overcoming the limitations of traditional biopsies. By supporting image-guided biopsies, this tracer facilitates HER2 reclassification, empowering better clinical decisions and driving treatment decisions.. For HER2-null and low metastatic breast or gastric cancer patients, it ensures accurate diagnosis to avoid undertreatment due to tumour heterogeneity. For HER2-positive patients, the tracer enables monitoring of treatment efficacy and adapting therapy if HER2 expression changes under treatment.